Industry
Biotechnology
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 3:45 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:27 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:48 pm
Portfolio Pulse from Avi Kapoor
July 18, 2024 | 5:19 pm
Portfolio Pulse from Avi Kapoor
July 18, 2024 | 10:00 am
Portfolio Pulse from Avi Kapoor
July 17, 2024 | 5:28 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 3:22 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 1:23 pm
Portfolio Pulse from Benzinga Insights
June 17, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
May 21, 2024 | 6:22 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.